SEATTLE — In this Healio Video Perspective from the ARVO meeting, Allen C. Ho, MD, FASRS, discusses 12-month data on MCO-010 optogenetic therapy for patients with retinitis pigmentosa.
According to Ho, patients who received high- and low-dose MCO-010 (Nanoscope Therapeutics) saw “significant visual acuity improvements” vs. sham. The safety profile was also promising, with no reported cases of severe inflammation, retinal vasculitis, occlusive vasculitis or optic neuropathies.
“This is a mutation agnostic program. That means it seems to be working regardless of whether or not you have a specific type of RP mutation,” he said. “That’s really important.”
A biologics license application for MCO-010 is expected to be submitted by the end of 2024 or the beginning of 2025.
Sources/Disclosures
Collapse
Ho A. Longitudinal BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 12-month results from a Phase 2b/3 randomized, sham-controlled, patient- and assessor-masked clinical trial (RESTORE). Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Disclosures:
Ho reports being a scientific advisor for Nanoscope Therapeutics and other companies in the gene and cell therapy space.